Galmed pharmaceuticals to report fourth quarter and year end 2020 financial results and provide business update on thursday march 18

Tel aviv, israel, march 11, 2021 /prnewswire/ -- galmed pharmaceuticals ltd. (nasdaq: glmd) ("galmed" or the "company"), a clinical-stage biopharmaceutical company focused on the development of aramchol, a liver targeted, oral, scd1 modulator, currently in phase 3 clinical trial for the treatment of nonalcoholic steatohepatitis (nash) and fibrosis announced today that it will host a conference call and webcast on thursday, march 18, 2021, to provide an update on current developments with respect to its clinical programs for aramchol™ and to discuss financial results for the quarter and year ended december 31, 2020.
GLMD Ratings Summary
GLMD Quant Ranking